title: Endophthalmitis after anti-VEGF injections.
authors.forename: Kathryn S
authors.initials: KS
authors.lastname: Klein
authors.forename: Mark K
authors.initials: MK
authors.lastname: Walsh
authors.forename: Tarek S
authors.initials: TS
authors.lastname: Hassan
authors.forename: Lawrence S
authors.initials: LS
authors.lastname: Halperin
authors.forename: Alessandro A
authors.initials: AA
authors.lastname: Castellarin
authors.forename: Daniel
authors.initials: D
authors.lastname: Roth
authors.forename: Sarah
authors.initials: S
authors.lastname: Driscoll
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Prenner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000009:adverse effects; D000068258:Bevacizumab; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D000069579:Ranibizumab; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab